0001209191-21-028200.txt : 20210423 0001209191-21-028200.hdr.sgml : 20210423 20210423204931 ACCESSION NUMBER: 0001209191-21-028200 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210421 FILED AS OF DATE: 20210423 DATE AS OF CHANGE: 20210423 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Spear Matthew A. CENTRAL INDEX KEY: 0001766302 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39376 FILM NUMBER: 21851177 MAIL ADDRESS: STREET 1: C/O POSEIDA THERAPEUTICS, INC. STREET 2: 4242 CAMPUS POINT COURT, SUITE 700 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Poseida Therapeutics, Inc. CENTRAL INDEX KEY: 0001661460 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472846548 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-779-3100 MAIL ADDRESS: STREET 1: 9390 TOWNE CENTRE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-04-21 0 0001661460 Poseida Therapeutics, Inc. PSTX 0001766302 Spear Matthew A. C/O POSEIDA THERAPEUTICS, INC. 9390 TOWNE CENTRE DRIVE, STE 200 SAN DIEGO CA 92121 0 1 0 0 Chief Medical Officer Common Stock 2021-04-21 4 M 0 4000 1.322 A 15485 D Common Stock 2021-04-21 4 S 0 4000 8.438 D 11485 D Common Stock 2021-04-23 4 M 0 5000 1.322 A 16485 D Stock Option (Right to Buy) 1.322 2021-04-21 4 M 0 4000 0.00 D 2026-06-19 Common Stock 4000 128861 D Stock Option (Right to Buy) 1.322 2021-04-23 4 M 0 5000 0.00 D 2026-06-19 Common Stock 5000 123861 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.32 to $8.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is fully vested and exercisable. /s/ Johanna Mylet, Attorney-in-Fact 2021-04-23